Bharat Biotech Covaxin recognized in Japan to facilitate travel from April 10
Advertisement
Tokyo: Japan has decided to recognise India's Covid-19 vaccine, Covaxin, with effect from April 10 to further facilitate travel from both the countries, said the Indian Embassy in Japan on Thursday.
Taking to Twitter, the embassy wrote, "Government of Japan includes the indigenously developed and manufactured COVID-19 vaccine COVAXIN by Bharat Biotech of India, as one of the recognised vaccines for 1st and 2nd dose with effect from 10 April 2022 to further facilitate travel from India to Japan."
Notably, Prime Minister Narendra Modi and his Japanese counterpart Fumio Kishida welcomed the Quad Leaders' Summits in March 2022 and September 2021 and renewed their commitment to delivering tangible outcomes on the Quad's positive and constructive agenda, especially on COVID vaccines, critical and emerging technologies, climate action, infrastructure coordination, cybersecurity, space, and education.
They looked forward to advancing Quad cooperation through the next Quad Leaders' Summit in Japan in the coming months.
In late March, the two leaders reaffirmed the importance of collaborative projects between the two countries in the Indo-Pacific region and looked forward to the expansion of such projects to ASEAN, Pacific island countries and others.
Issuing a joint press statement, the two leaders also acknowledged the progress in the ongoing projects in Bangladesh.
"The Prime Ministers reaffirmed the significance of collaborative projects between India and Japan in the Indo-Pacific region. They acknowledged the progress in ongoing projects in Bangladesh and looked forward to exploring expansion of such cooperation to ASEAN, Pacific island countries and others," the press statement said.
Japanese Prime Minister Fumio Kishida also used the opportunity to welcome India's Indo-Pacific Oceans' Initiative (IPOI) launched by Prime Minister Narendra Modi in 2019. The main objective of the IPOI is to ensure the safety, security, and stability of the maritime domain.
Read also: Bharat Biotech and Ocugen to bring Covaxin in US and Canada
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.